EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessing Dose- and Sex-Dependent Antinociceptive Effects of Cannabidiol and Amitriptyline, Alone and in Combination, and Exploring Mechanism of Action Involving Serotonin 1A Receptors

Robert C Barnes, Satish Banjara, Melissa C McHann, Sharilyn Almodovar, Angela N Henderson-Redmond, Daniel J Morgan, Isabel Castro-Piedras, Josée Guindon iD

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.001855 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Robert C Barnes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Neuroscience (R.C.B., S.B., M.C.M., I.C.-P., J.G.), Department of Immunology and Molecular Microbiology (S.A.), and Ce…. Hauptthemen laut MEDLINE: Cannabidiol, Chronic Pain. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory pain is caused by tissue hypersensitization and is a component of rheumatic diseases, frequently causing chronic pain. Current guidelines use a multimodal approach to pain and sociocultural changes have renewed interest in cannabinoid use, particularly cannabidiol (CBD), for pain. The tricyclic antidepressant amitriptyline (AT) is approved for use in pain-related syndromes, alone and within a multimodal approach. Therefore, we investigated sex- and dose-dependent effects of CBD and AT antinociception in the 2.5% formalin inflammatory pain model. Male and female C57BL/6J mice were pretreated with either vehicle, CBD (0.3-100 mg/kg), or AT (0.1-30 mg/kg) prior to formalin testing. In the acute phase, CBD induced antinociception after administration of 30-100 mg/kg in males and 100 mg/kg in females and in the inflammatory phase at doses of 2.5-100 mg/kg in males and 10-100 mg/kg in females. In the acute phase, AT induced antinociception at 10 mg/kg for all mice, and at 0.3 mg/kg in males and 3 mg/kg in female mice in the inflammatory phase. Combining the calculated median effective doses of CBD and AT produced additive effects for all mice in the acute phase and for males only in the inflammatory phase. Use of selective serotonin 1A receptor antagonist N-[2-[4-(2-methoxyphenyl)-1 piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY-100635) maleate (0.1 mg/kg) before co-administration of CBD and AT reversed antinociception in the acute and partially reversed antinociception in the inflammatory phase. Administration of AT was found to enhance cannabinoid receptor type 1mRNA expression only in female mice. These results suggest a role for serotonin and sex in mediating cannabidiol and amitriptyline-induced antinociception in inflammatory pain. SIGNIFICANCE STATEMENT: Inflammatory pain is an important component of both acute and chronic pain. We have found that cannabidiol (CBD) and amitriptyline (AT) show dose-dependent, and that AT additionally shows sex-dependent, antinociceptive effects in an inflammatory pain model. Additionally, the combination of CBD and AT was found to have enhanced antinociceptive effects that is partially reliant of serotonin 1A receptors and supports the use of CBD within a multimodal approach to pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolChronic PainMiceMaleFemaleAnimalsSerotoninAmitriptylineReceptor, Serotonin, 5-HT1AMice, Inbred C57BLSerotonin AntagonistsAnalgesicsFormaldehyde

Substanzen

CannabidiolSerotoninAmitriptylineReceptor, Serotonin, 5-HT1ASerotonin AntagonistsAnalgesicsFormaldehyde

Autor:innen und Institutionen

  • Department of Pharmacology and Neuroscience (R.C.B., S.B., M.C.M., I.C.-P., J.G.), Department of Immunology and Molecular Microbiology (S.A.), and Center of Excellence for Translational Neuroscience and Therapeutics (J.…

ORCID-Profile: Josée Guindon

Förderung

  • NIDA NIH HHS

Zitieren

APA

Barnes, R. C., Banjara, S., McHann, M. C., Almodovar, S., Henderson-Redmond, A. N., Morgan, D. J., Castro-Piedras, I., & Guindon, J. (2024). Assessing Dose- and Sex-Dependent Antinociceptive Effects of Cannabidiol and Amitriptyline, Alone and in Combination, and Exploring Mechanism of Action Involving Serotonin 1A Receptors. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001855

Vancouver

Barnes RC, Banjara S, McHann MC, Almodovar S, Henderson-Redmond AN, Morgan DJ, et al. Assessing Dose- and Sex-Dependent Antinociceptive Effects of Cannabidiol and Amitriptyline, Alone and in Combination, and Exploring Mechanism of Action Involving Serotonin 1A Receptors. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001855

BibTeX
@article{Barnes2024,
  author = {Barnes, Robert C and Banjara, Satish and McHann, Melissa C and Almodovar, Sharilyn and Henderson-Redmond, Angela N and Morgan, Daniel J and Castro-Piedras, Isabel and Guindon, Josée},
  title = {Assessing Dose- and Sex-Dependent Antinociceptive Effects of Cannabidiol and Amitriptyline, Alone and in Combination, and Exploring Mechanism of Action Involving Serotonin 1A Receptors},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.001855}
}
Kostenlos starten →